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Abstract: Venom peptides found in terebrid snails expand the toolbox of active compounds that can
be applied to investigate cellular physiology and can be further developed as future therapeutics.
However, unlike other predatory organisms, such as snakes, terebrids produce very small quantities
of venom, making it difficult to obtain sufficient amounts for biochemical characterization. Here,
we describe the first recombinant expression and characterization of terebrid peptide, teretoxin Tgu6.1,
from Terebra guttata. Tgu6.1 is a novel forty-four amino acid teretoxin peptide with a VI/VII cysteine
framework (C–C–CC–C–C) similar to O, M and I conotoxin superfamilies. A ligation-independent
cloning strategy with an ompT protease deficient strain of E. coli was employed to recombinantly
produce Tgu6.1. Thioredoxin was introduced in the plasmid to combat disulfide folding and solubility
issues. Specifically Histidine-6 tag and Ni-NTA affinity chromatography were applied as a purification
method, and enterokinase was used as a specific cleavage protease to effectively produce high yields
of folded Tgu6.1 without extra residues to the primary sequence. The recombinantly-expressed Tgu6.1
peptide was bioactive, displaying a paralytic effect when injected into a Nereis virens polychaete
bioassay. The recombinant strategy described to express Tgu6.1 can be applied to produce high yields
of other disulfide-rich peptides.
Keywords: Terebridae; venom peptides; teretoxins; recombinant synthesis; polychaete assay;
disulfide-rich peptides; Conoidea; snail venom
1. Introduction
Venom peptides are a resource for investigating evolution, cellular communication and therapeutic
development [1–3]. The Terebridae are a family of venomous marine gastropods in the superfamily
Conoidea, which includes cone snails (family Conidae) and turrids (a complex family) [4–6]. Like most
conoideans, some terebrid species produce venoms that consist of greater than 100 different peptides
that are primarily used to capture prey [7–11]. Research of conoideans over the last three decades
largely focused on the venom peptides of cone snails (conotoxins) [11–13]. Collective biochemical
and pharmacological evidence has shown that conotoxins are both diverse and highly selective,
binding specifically to various ligand-gated and voltage-gated ion channel subtypes, including
Toxins 2016, 8, 63; doi:10.3390/toxins8030063 www.mdpi.com/journal/toxins
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sodium, potassium and calcium channels, and can be used as molecular probes and pharmaceutical
agents [10,14–16]. In contrast, the toxicology of terebrids has not yet attracted the same degree of
scientific attention. In large part, this is because terebrids are smaller and produce venom on the
nanogram scale. However, with technological advances, such as DNA and RNA sequencing, PCR and
molecular biology, it is now possible to investigate the primary sequences of terebrid venom peptides,
teretoxins, using an integrated venomics strategy that combines phylogenetics, transcriptomics and
proteomics [8,9,17,18]. Here, we describe the characterization of a novel teretoxin, Tgu6.1 from
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guttata  from which  the Tgu6.1  teretoxin was discovered.  (B) Plasmid map  of Tgu6.1  cloned  into  
pET‐32a  Xa/ligation  independent  cloning  (LIC)  vector  via  LIC.  (C)  RP‐HPLC  purification  of 
recombinant Tgu6.1  from  its  fusion  tag  after  expression,  purification  and  cleavage  (top  spectra);  
LC‐MS analysis of Tgu6.1 (bottom spectra). (D) Characterization of Tgu6.1 bioactivity using the native 
prey polychaete worm assay (view the video in Supplemental Material). 
Despite  the  potential  of  terebrid  venom  peptides,  given  the  small  size  of  terebrid  snails, 
obtaining  sufficient  amounts  of  venom  for  downstream  biochemical  characterization  remains  a 
significant challenge. After obtaining the primary sequence of venom peptides, solid phase peptide 
synthesis (SPPS) and recombinant expression are often applied to produce synthetic versions of the 
peptides  for  investigation  [21–23]. SPPS has  the advantage of being able  to  incorporate unnatural 
amino acids and accommodating posttranslational modifications. Traditionally, SPPS was restricted 
to direct synthesis to peptides of <50 amino acids; however, modern advances, such as microwave 
synthesis  and  peptide  ligation methods,  have  extended  the  size  of  peptides made  synthetically 
significantly to <100 amino acids [24–28]. Teretoxins are generally larger than conotoxins, ranging in 
size up to 70 amino acids, which places them at the upper limits of SPPS and, therefore, are appealing 
Figure 1. Recombinant expression and characterization of Tgu6.1 teretoxin. (A) Terebrid snail
Terebra guttata from which the Tgu6.1 teretoxin was discovered. (B) Plasmid map of Tgu6.1 cloned
into pET-32a Xa/ligation independent cloning (LIC) vector via LIC. (C) RP-HPLC purification of
recombinant Tgu6.1 from its fusion tag after expression, purification and cleavage (top spectra); LC-MS
analysis of Tgu6.1 (bottom spectra). (D) Characterization of Tgu6.1 bioactivity using the native prey
polychaete worm assay (view the video in Supplemental Material).
Teretoxins and conotoxins, while similar in molecular structure, are not homologous. Teretoxins
differ from conotoxins in size, complexity and structural integrity, suggesting possible diverse
molecular applications [7,19,20]. Recently, mature teretoxins from Terebra subulata and Hastula hectica
were identified with cysteine frameworks similar to those found in conotoxins, but without signal
sequence homology, suggesting divergence in the venom peptide evolution [20]. Additionally, recent
isolation and structural characterization of teretoxin Tv1 from Terebra variegata identified Tv1 as similar
to M-superfamily conotoxins; however, Tv1 has a unique fold and disulfide-bonding pattern not
previously found in venom peptides [2]. These findings suggest that teretoxins are a promising
resource to increase the venom peptide toolbox.
Despite the potential of terebrid venom peptides, given the small size of terebrid snails, obtaining
sufficient amounts of venom for downstream biochemical characterization remains a significant
challenge. After obtaining the primary sequence of venom peptides, solid phase peptide synthesis
(SPPS) and recombinant expression are often applied to produce synthetic versions of the peptides
for investigation [21–23]. SPPS has the advantage of being able to incorporate unnatural amino
acids and accommodating posttranslational modifications. Traditionally, SPPS was restricted to
direct synthesis to peptides of <50 amino acids; however, modern advances, such as microwave
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synthesis and peptide ligation methods, have extended the size of peptides made synthetically
significantly to <100 amino acids [24–28]. Teretoxins are generally larger than conotoxins, ranging
in size up to 70 amino acids, which places them at the upper limits of SPPS and, therefore, are
appealing candidates for recombinant expression. There are several examples in the literature of the
recombinant expression of short disulfide-rich peptides [23,29–39]. Table 1 highlights the different
aspects of the recombinant expression that must be considered, such as the choice of fusion tag,
purification method, host species and strain and method of cleavage. In this study, we outline a
strategy for recombinantly-expressing teretoxins with the first successful recombinant expression and
purification of teretoxin Tgu6.1 (Figure 1). Teretoxin Tgu6.1 is a novel forty-four amino acid peptide
from Terebra guttata with a VI/VII cysteine framework (C–C–CC–C–C), which can also be found in the
conotoxin M-, I- and O-superfamilies [40–44]. The bioactivity of Tgu6.1 was also characterized using
a bioassay of native prey Nereis virens polychaete worms. The recombinant strategy outlined can be
readily applied to other teretoxins and disulfide-rich peptides.
Table 1. Comparison of recombinant expression strategies for disulfide-rich peptides. Main features
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Thioredoxin His tag Soluble BL21 (DE3) Enterokinase Wu et al.,2014 [39]
2. Results and Discussion
2.1. Design and Construction of Teretoxin Tgu6.1 Expression System
Tgu6.1 was obtained and identified on the genetic level as its full precursor sequence using
RNA-Seq (Figure 2A). The mature peptide Tgu6.1 was expressed as a fusion protein sequentially
composed of an N-terminal thioredoxin tag, Histidine-6 (His6) tag and enterokinase (EK) site
(Figure 2B). Small cysteine-rich peptides are difficult to overexpress in Escherichia coli due to the
formation of insoluble protein aggregates or inclusion bodies, proteolytic degradation and reducing
conditions in the E. coli cytoplasm that hinder the formation of disulfide bonds [14]. Several choices
were made in the design of the expression system of Tgu6.1 to mitigate these issues.




Figure  2. Recombinant  expression  strategy of Tgu6.1.  (A) Full precursor  structure of Tgu6.1. The 
signal sequence is shaded in gray; the pro‐region is underlined; and the mature peptide is shaded in 
blue. (B) Schematic representation of Tgu6.1 fusion protein. The fusion protein was expressed under 
the control of a pET‐32a T7 promoter and contains  thioredoxin as  the  fusion partner, His6‐tag  for 
purification  and  the  enterokinase  (EK)  site  for  the  cleavage of Tgu6.1  from TRX by  enterokinase.  
(C) Plasmid map of the expression vector. The Tgu6.1 gene was cloned into pET‐32a XA/LIC plasmid 
by ligation independent cloning. 
Specifically,  solubility  was  addressed  by  the  cloning  of  the  Tgu6.1  gene  into  thioredoxin 
containing pET‐32a XA/LIC vector using ligation independent cloning (LIC) (Figure 2C). Thioredoxin 
as a fusion partner has been shown to significantly increase the solubility of proteins synthesized in 
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Expression  of  Tgu6.1  fusion  protein  was  induced  by  addition  of  0.4  mM  isopropyl  
β‐D‐1‐thiogalactopyranoside (IPTG) during log phase growth, at 25 °C. After overnight expression 
and  subsequent  lysis by  sonication,  the  fusion protein was purified  from  the  soluble  fraction by  
Ni‐NTA  (Nickel‐NitriloTriacetic  Acid)  affinity  chromatography  batch‐wise  and  under  native 
i r . eco binant expression strategy of Tgu6.1. (A) Full precursor structure of Tgu6.1. The signal
sequence is shaded in gray; the pro-region is u derli ed; and the mature peptide is shaded in blue.
(B) Schematic representation of Tgu6.1 fusion protein. The fusion protein was ex resse n er
the control of a pET-32a T7 pro oter and contains thioredoxin as the fusion partner, is6-tag for
purification and the enterokinase (EK) site for the cleavage of Tgu6.1 fro TRX by enterokinase.
(C) Plas id ap of the expression vector. The Tgu6.1 gene as cloned into pET-32a XA/LIC plas id
by ligation independent cloning.
cific ll , solubility was address d by the cloning of the Tgu6.1 gene into thioredoxin c ntaining
pET-32a XA/LIC vector using ligation independent cloning (LIC) (Figure 2C). Thioredoxin as a fusio
partner has bee shown to significantly i cre se the solubility of proteins synth sized in the E. coli
cytoplasm [30,45–48]. Furthermore, when expressed i an oxidizing environment, thiored xin has
been observed to catalyze disulfide bond formation [49]. Proteolytic degradation was attenuated by
expressing the fusion protein in an ompT protease-deficient E. coli strain, Origami B (DE3). This strain
also provides the oxidizing cytoplasmic environment necessary for disulfide bond formation via its
double (trxB´, gor´) mutation [50]. To further optimize expression, the Tgu6.1 gene was reverse
translated from the amino acid sequence to codons optimized for E. coli bacterial expression. A His6-tag
was provided by the pET-32a Xa/LIC vector for urification of the fusi n protein via immobilized metal
affinity chro atography. Finally, an enterokinase site was added directly to the N-terminus of Tgu6.1
allowing for fusion peptide cleavage without excess residues on the cleaved Tg 6.1 peptide product.
2.2. Expression and Purification of Tgu6.1
Expression of Tgu6.1 fusion protein was induced by addition of 0.4 mM isopropyl
β-D-1-thiogalactopyranoside (IPTG) during log phase growth, at 25 ˝C. After overnight expression
and subsequent lysis by sonication, the fusion protein was purified from the soluble fraction by
Toxins 2016, 8, 63 5 of 12
Ni-NTA (Nickel-NitriloTriacetic Acid) affinity chromatography batch-wise and under native conditions.
The 23.77-kDa fusion protein was eluted with 500 mM imidazole, and its overexpression and purity
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M = protein molecular weight marker; Lane 1 =  cell  lysate; Lane 2 =  supernatant post‐binding  to  
Ni‐NTA  resin;  Lane  3  =  Wash  Buffer  1  supernatant;  Lane  4  =  Wash  Buffer  2  supernatant;  
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major  peaks  were  observed  at  12.7  and  18  min  (Figure  3C).  Liquid  chromatography  mass 
spectrometry (LC‐MS) confirmed that the two peaks observed were the oxidized Tgu6.1 and the TRX 
fusion  tag,  respectively.  The  12.7‐min  peak  corresponding  to  the  oxidized  Tgu6.1  displayed  a 
Figure 3. Expression and purification of Tgu6.1. (A) 12% SDS-PAGE Coomassie-stained gel showing
expression and purification of Tgu6.1 fusion protein by Ni-NTA affinity chromatography. M = protein
molecular weight marker; Lane 1 = cell lysate; Lane 2 = supernatant post-binding to Ni-NTA resin;
Lane 3 = Wash Buffer 1 supernatant; Lane 4 = Wash Buffer 2 supernatant; Lane 5 = imidazole
eluted fraction. (B) Tris-tricine 16.5% SDS-PAGE Coomassie-stained gel showing Tgu6.1 cleavage
by enterokinase. M = protein molecular weight marker; Lanes 1–3, enterokinase cleavage in 1:50,
1:20 and 1:10 dilutions. (C) Chromatogram of RP-HPLC purification of Tgu6.1 from TRX fusion
tag. An X-Bridge C18 semi-preparative column was used with Buffer A (0.1% TFA) and Buffer B
(80% ACN/0.1% TFA). The peptide was eluted with a linear gradient of 5%–75% Buffer B over 30 min
at a flow rate of 5 mL/min. (D) LC-MS characterization of folded Tgu6.1. The +4, +5, +6 and +7 ion
charge states are shown. Expected mass = 4758.58 Da. Observed mass = 4758.28 Da.
Following ultrafiltration and buffer exchange, the fusion protein was cleaved with recombinant
enterokinase. Cleavage was observed by Tris-tricine SDS-PAGE with the appearance of two bands
at 20 kDa and 4.8 kDa, corresponding to the fusion tag and cleaved Tgu6.1, respectively (Figure 3B).
Cleavage conditions were optimized with the addition of urea, as inaccessibility to the cleavage site
has been shown to favor advantageous non-specific cleavage [51]. Partial denaturation by urea both
improved the yield of cleaved Tgu6.1 and reduced non-specific cleavage significantly.
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Fusion free Tgu6.1 was then purified and collected by reverse-phase HPLC (RP-HPLC). Two major
peaks were observed at 12.7 and 18 min (Figure 3C). Liquid chromatography mass spectrometry
(LC-MS) confirmed that the two peaks observed were the oxidized Tgu6.1 and the TRX fusion tag,
respectively. The 12.7-min peak corresponding to the oxidized Tgu6.1 displayed a monoisotopic
mass of 1190.57 m/z, which is the M + 4H charge corresponding to a mass of 4758.28 Da, which is
consistent with the predicted mass of 4758.58 Da for fully-oxidized Tgu6.1. The M + 5H, M + 6H and
M + 7H charged states were also observed (Figure 3D). Expression of Tgu6.1 in the Origami host gave
an average yield of 20.9 mg per liter of growth medium.
2.3. Polychaete Functional Assay
The bioactivity of Tgu6.1 was examined using a Nereis virens polychaete bioassay. Polychaetes,
such as N. virens, are the natural prey of terebrid snails and were previously shown to be a viable
assay for determining the bioactivity of teretoxins [9,19]. The polychaete bioassay provides a global
phenotypic detection of teretoxin bioactivity by observing the behavioral response of the worm to
treatment with the peptide. Polychaetes are also readily available in laboratory cultures and also
widely used to examine the toxicity of organic chemicals [51].
Under standardized conditions, 10 µmoles/g of novel synthetic teretoxin Tgu6.1 were injected into
the central nerve cord of each polychaete worm (Figure 4). Polychaetes injected with Tgu6.1 resulted
in a significantly lower average moving speed than non-injected (2.189 ˘ 0.199 vs. 5.975 ˘ 0.225; df = 2,
F = 107.6; p-value < 0.0001) and saline-injected worms (2.189˘ 0.199 vs. 6.526˘ 0.256; p-value < 0.0001).
Saline-injected and non-injected worms did not show significance (p-value of 0.201). These findings
indicate that there is strong evidence that Tgu6.1 caused a paralytic effect in N. virens.
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The  Tgu6.1  mature  peptide  sequence  obtained  from  RNASeq  (GenBank  Accession  
Number  KU738608)  was  optimized  for  E.  coli  codon  usage.  The  synthetic  Tgu6.1  insert  was  
ordered  from  Integrated  DNA  Technologies  (IDTDNA).  The  gene  insert  was  amplified  
using  primers  5′‐GGTATTGAGGGTCGCATATTATATTATTTA‐3′  and  
5′‐AGAGGAGAGTTAGAGCCATAATAATATTTA‐3′  (IDTDNA),  which  contained  the  requisite 
ligation‐independent cloning (LIC); overhangs underlined in the sequence above. 
The  PCR  amplified  insert was  purified with  SpinPrep Gel DNA Kit  (Novagen, Darmstadt, 
Germany) and cloned via LIC into vector pET‐32 Xa/LIC (EMD Millipore, Darmstadt, Germany). The 
Figure 4. Representative centromeres and average moving speed. (A) Visualization of the movement
of the polychaetes for ten minutes after injection. (B) Graph depicting the mean and standard error of
the average speeds. The * represents p-values less than 0.05.
3. Experimental Section
3.1. Construction of Recombinant Plasmid
The Tgu6.1 mature peptide sequence obtained from RNASeq (GenBank Accession
Number K 738608) was optimized for E. coli codon usage. The synthetic Tgu6.1
insert was ordered from Integrated DNA Technologies (IDTDNA). The gene insert
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was amplified using primers 51-GGTATTGAGGGTCGCATATTATATTATTTA-31 and
51-AGAGGAGAGTTAGAGCCATAATAATATTTA-31 (IDTDNA), which contained the requisite
ligation-independent cloning (LIC); overhangs underlined in the sequence above.
The PCR amplified insert was purified with SpinPrep Gel DNA Kit (Novagen, Darmstadt,
Germany) and cloned via LIC into vector pET-32 Xa/LIC (EMD Millipore, Darmstadt, Germany).
The insert was treated for 30 min at 22 ˝C with T4 DNA polymerase at 0.5 unit per 0.1 pmol/µL of
insert in TlowE (Tris-low- EthyleneDiamineTetraAcetic acid (EDTA)) buffer (10 mM Tris HCl, 0.1 mM
EDTA, pH 8.0) with 2.5 mM dGTP and 5 mM DTT. The enzyme was inactivated at 75 ˝C for 20 min.
The T4 DNA polymerase-treated insert was annealed into the Xa/LIC vector at 22 ˝C for 5 min. Then,
7.25 mM EDTA was added, and the components were stirred with a pipet tip for another 5 min at
22 ˝C. The pET-32 Xa/LIC:Tgu6.1 plasmid construct was transformed into E. coli NovaBlue obtained
from Novagen. Positive clones were screened for via ampicillin and kanamycin resistance. Insertion
was verified by colony PCR (EMD Millipore) and DNA sequencing. For colony PCR, single colonies
of screened positive clones were suspended in 50 µL of water, incubated at 99 ˝C for 5 min and
centrifuged at 12,000ˆ g for 1 min. Ten microliters of supernatant were used for PCR using the T7
promoter and the T7 terminator (IDTDNA) as the forward and reverse primers, respectively.
3.2. Induction and Expression
The pET-32 Xa/LIC:Tgu6.1 plasmid construct verified by colony PCR and DNA sequencing was
transformed into E. coli Origami (Novagen) for expression. A single colony from a fresh plate was
used to inoculate a primary culture of LB media containing tetracycline (12.5 µg/mL) and ampicillin
(50 µg/mL). The primary culture was grown overnight at 37 ˝C with shaking at 250 RPM. A larger
culture was inoculated using the overnight pre-culture. The cells were incubated at 37 ˝C and 250 RPM
until the OD600 was between 0.8 and 1.0. Isopropyl β-D-1-thiogalactopyranoside was then added
to a final concentration of 0.4 mM to induce the expression of the fusion protein. The culture was
incubated overnight at 25 ˝C and 250 RPM for overexpression of soluble protein. The cells were
harvested by centrifugation (8000ˆ g, 10 min, 4 ˝C), and the pellet was stored at ´20 ˝C until use.
3.3. Protein Extraction and His-Tag Affinity Purification
The bacterial pellet of E. coli Origami transformed with the pET-32 Xa/LIC:Tgu6.1 plasmid
construct was resuspended in sodium phosphate buffer (100 mM Na-PO4, pH 8.0, 300 mM NaCl,
10% glycerol) and lysed by sonication using Fisher Scientific (Hampton, VA, USA) Model 120 Sonic
Dismembrator with three rounds at 70% power for 30 s and three rounds at 90% power for 30 s for
soluble protein extraction. Cleared lysate was generated by centrifugation at 13,000ˆ g for 45 min.
The supernatant was purified with a batch purification method using nickel-NTA resin (Qiagen,
Hilden, Germany) pre-equilibrated with lysis buffer (100 mM Na-PO4, 300 mM NaCl, 10% glycerol,
1 mg/mL lysozyme, pH 8.0). Binding of cleared fusion protein lysate to nickel-NTA resin was followed
by treatment with two wash buffers: Wash Buffer 1 (50 mM Na-PO4 pH 7.7, 300 mM NaCl, 10 mM
imidazole, 10% glycerol) and Wash Buffer 2 (50 mM NaPO4 pH 7.7, 2M NaCl, 10 mm imidazole,
10% glycerol). His-tagged protein was eluted sequentially with two elution buffers, Elution Buffer 1
(50 mM Na-PO4 pH 7.7, 300 mM NaCl, 20 mM imidazole) and Elution Buffer 2 (50 mM Na-PO4 pH
7.7, 300 mM NaCl, 500 mM imidazole, 10% glycerol). Fusion protein was desalted by buffer exchange
to 1ˆ phosphate buffer saline (PBS) via ultrafiltration (10 kDa MWCO, Sigma-Aldrich, St. Louis, MO,
USA). Expression and purification were analyzed by SDS-PAGE (Bio-Rad Laboratories, Hercules,
CA, USA).
3.4. Enterokinase Cleavage
The purified fusion protein was cleaved by enterokinase protease (EMD Millipore and Syd Labs).
Cleavage was incubated overnight at an enzyme:substrate ratio of 1:50 in EK cleavage capture buffer
(50 mM NaCl, 20 mM Tris-HCl, 2 mM CaCl2, pH 7.4). Cleavage yield was enhanced by the addition
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of urea to a final concentration of 1 to 4 M; optimal cleavage was observed at a final concentration of
3 M urea.
3.5. RP-HPLC Purification and Mass Spectrometry
Cleaved Tgu6.1 was purified by RP-HPLC (Agilent, Santa Clara, CA, USA) using an X-Bridge
C18 semi-preparative column (10 ˆ 150 mm, 5-µm particle size, Waters Corporation, Milford, MA,
USA) pre-equilibrated with 95% Buffer A (0.1% TFA). Elution was carried out at 5 mL/min over
a linear gradient of Buffer B (80% acetonitrile 0.1% TFA) from 5% to 75% in 30 min. ESI-mass
spectra were recorded on an Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS. Samples
were delivered to the mass spectrometer through chromatographic separation on the Agilent HPLC
1290, and monoisotopic average masses of peptides were calculated from sequence information
using the UCSF ProteinProspector MS-Product tool ([52], San Francisco, CA, USA). Observed mass
was calculated from m/z charged states using MassHunter Bioconfirm Qual B.06 software (Agilent,
Santa Clara, CA, USA, 2012).
3.6. Polychaete Worm Assay
A Nereis virens polychaete bioassay was used to examine the bioactivity of Tgu6.1. For benchmark
trials of each experiment, three N. virens were placed in cold saltwater solution (4 ˝C), with a 20-min
acclimation period, preceding the injection. The acclimation period accustomed polychaetes to their
experimental environment, thus shifting the worms from salt-water solution (4 ˝C) to room temperature
(25 ˝C), stimulating the phenotypic response. Worms used were comparable in size (<9.0 g, <9 cm)
to ensure consistency of activity upon teretoxin injection. Control worms were injected with 2 µL of
substance per 2 g of normal saline solution (NSS). Tgu6.1 teretoxin was dissolved in NSS and diluted to
20 µM aliquots. Three worms were used for each experimental condition: non-injected, saline solution
and Tgu6.1; and the experiment was repeated in triplicate. Worms were injected with teretoxin using
B-D (Becton Dickinson, Franklin Lakes, NJ, USA) ½ cc LO-DOSE U-100 insulin plastic syringe 28 G 1/2
(0.36 mm ˆ 13 mm) with altered needle caps, to manage a uniform 1.0-mm depth of needle puncture.
To target the ventral nerve cord, subjects were injected between the 5th and 7th segment of the ventral
anterior end. Phenotypic worm movement and behavior were recorded on video for a duration of
2.5 h and were used to assess the effects of each teretoxin injection. Post-injection, polychaetes showed
excitatory movement at room temperature, whereas injections with salt-water solution had a sedating
result. Changing temperatures distinguished the variability in overall spatial range of movement and
the average speed of the polychaetes. The first 10 min after each teretoxin Tgu 6.1 injection resulted in
partial paralysis of the polychaete worm.
Video recordings of each polychaete injection were analyzed frame-by-frame using an in-house
custom image segmentation algorithm to accurately separate worm contours from the underlying
pixel noise. The algorithm was implemented in Python using two open source computer vision
libraries: OpenCV and SimpleCV. The algorithm begins with a palletization function based on k-means
clustering to minimize the number of image segments expected to be seen in the video streams with
worm data. This step corrects for inaccuracies in the image segments in frames with high noise.
The video stream-specific palette generated is then used to segment each image frame into multiple
contours. The worm contours are obtained by filtering out the non-worm contours by size, color and
position. The mass weighted centroids are then calculated for each worm contour obtained. This is
then further utilized to obtain per-frame worm centroid movement speed. The pseudocode for the
image segmentation algorithm used is shown below.
Pseudocode describing in-house image segmentation algorithm to analyze polychaete movement:
randomFrame ď videoStream
FUNCTION LearnPalette(randomFrame, [binSize1, binSize2, ..., binSizeN])
RETURN optimalNumberOfImageSegments, learnedPalette
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ENDFUNCTION
FOR frame ď videoStreamStart TO videoStreamEnd
FUNCTION FindCountoursWithPalette(frame, learnedPalette)
IF foundCountours > optimalNumberOfImageSegments THEN
newOptimalNumberOfImageSegments, newPalette~=~LearnPalette(frame,
















Venom peptides from terebrid snails increase the toolbox of bioactive compounds that can be used
to characterize cellular communication and potentially applied to the development of therapeutics
for improving human health. Unlike snakes, terebrid snails produce nanogram quantities of venom,
making it difficult to obtain sufficient amounts for biochemical characterization. Here, we describe the
first recombinant expression of a teretoxin and characterize the bioactivity of novel Tgu6.1 teretoxin
from Terebra guttata.
To produce Tgu6.1 recombinantly, a ligation independent cloning strategy with an ompT
protease-deficient strain of E. coli as a vector to express Tgu6.1 was employed. Several considerations
in plasmid design where made to combat common challenges associated with recombinant expression,
such as the formation of insoluble protein aggregates in E. coli, proteolytic degradation and unfavorable
conditions in E. coli cytoplasm that can prevent the formation of disulfide bonds. Recombinant
expression of Tgu6.1 provided an average yield of 20.9 mg per liter of growth medium to apply
for bioactivity assays (Figure 1). This carefully constructed recombinant design can be used as an
alternative to solid phase peptide synthesis of teretoxins and other disulfide-rich peptides. As research
in venom peptides for therapeutic drug development increases, it is crucial to have reliable methods
for obtaining significant amounts of disulfide-rich peptides.
While Tgu6.1 requires further characterization to identify its specific molecular target, we have
successfully demonstrated its paralytic activity in an N. virens polychaete bioassay. Prior research
of teretoxin Tv1 from Terebra variegata also produced paralytic activity in a similar polychaete assay,
and characterization of crude terebrid venom extract from several species suggests that a possible
molecular target for teretoxins could be nicotinic receptors [8,17,18]. Taken together, the results
from this work demonstrate that teretoxins are promising venom peptides that can be recombinantly
expressed for biochemical characterization.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/8/3/63/s1.
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